New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 31, 2014
14:00 EDTHALO, BAXBaxter, Halozyme announce favorable FDA panel recommendation on HyQvia
Baxter International (BAX) and Halozyme Therapeutics (HALO) announced that the Blood Products Advisory Committee of the FDA voted 15-1 that HyQvia, Baxter’s investigational subcutaneous treatment for patients with primary immunodeficiency, has a favorable risk/benefit profile. ''We are hopeful that the positive support for HyQvia is the next step toward providing a new treatment option for patients with primary immunodeficiency in the United States. We look forward to working closely with the FDA as it completes its review,'' said Ludwig Hantson, Ph.D., president of Baxter BioScience. HyQvia was approved in Europe in 2013 for adults with primary immunodeficiency syndromes and myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections. HyQvia is a product consisting of human normal immunoglobulin and recombinant human hyaluronidase, licensed from Halozyme.
News For BAX;HALO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
10:06 EDTBAXHigh option volume stocks
High option volume stocks: GLOG ACI NGD BEAT BAX TTPH STJ FNF SSTK
August 24, 2015
08:31 EDTHALOHalozyme names Michael LaBarre chief scientific officer
Halozyme named Michael J. LaBarre, Ph.D. as chief scientific officer, succeeding Dr. Michael Shepard, who was appointed a Research Fellow for the company. "Mike has deep experience characterizing early stage assets, making him an ideal leader for our research organization as we invest further in our promising pipeline," said Dr. Helen Torley, president and chief executive officer. "We have a full agenda for the second half of 2015 as we broaden the study of our investigational new drug PEGPH20 in multiple tumor types and prepare for our pivotal phase 3 study in pancreatic cancer patients. I am pleased to have a proven leader of Mike's caliber to guide our research efforts as we invest for future growth."

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use